According to the Centers for Disease Control (CDC), people are considered fully vaccinated for COVID-19 two weeks after they have received the second dose in a two-dose series (e.g., Pfizer/BioNTech or Moderna), or two weeks after they have received a single-dose vaccine (e.g., Johnson & Johnson’s/Janssen).
Vaccination guidance applies to COVID-19 vaccines authorized for use and for emergency use by the U.S. Food and Drug Administration (i.e., Pfizer-BioNTech, Moderna, and Johnson and Johnson (J&J)/Janssen COVID-19 vaccines), and COVID-19 vaccines authorized for emergency use by the World Health Organization (WHO) (i.e. Pfizer-BioNTech, Moderna, and Johnson and Johnson (J&J)/Janssen, Oxford/AstraZeneca, Covishield, Covaxin, Sinopharm/BBIBP-CorV, and Sinovac/CoronaVac), on or before February 15, 2022. The full list of vaccines with final WHO EUL/PQ evaluation status is available the World Health Organization.
ACS may expand the list of vaccines, provide more specific guidance regarding mixed vaccination dosing, and/or provide additional guidance regarding boosters as prevailing public health guidance evolves.